CRO giant Icon charted double-digit revenue growth in the third quarter, chugging toward its best-ever year and lifting its earnings projections in the process.
The patent cliff may still be taking a toll on Bristol-Myers Squibb, but the company's Q3 sales haul was enough to impress analysts thanks to star performances from a few key new products.
Edwards Lifesciences beat earnings expectations on the back of faster-than-expected growth in the company's core market of transaortic valve replacements for heart patients too frail for open-heart surgery. But company officials stressed that competitors are ramping up their efforts in that arena following recent product launches.
Shire is riding solo after AbbVie called it quits on its proposed $52 billion acquisition, but the company isn't shedding too many tears. The Dublin-based drugmaker announced third-quarter earnings that beat analysts' expectations, leaving the door open for success post-AbbVie.
Pfizer's $11 billion share buyback, announced late Thursday, gave investors something to focus on, rather than fretting about whether the company would renew its pursuit of AstraZeneca once the required cooling off period lapses in November. But some of them immediately started worrying about whether the buyback meant it was less likely Pfizer would do a big deal.
PetMed Express CEO Menderes Akdag raised a few eyebrows when he blamed his company's missed quarterly profit and sales targets on the weather.
VCA, which manages the largest network of veterinary hospitals and labs in the U.S., announced Thursday night that its revenues grew 7.7% to a record $499.6 million in the third quarter. The company credited the positive results in part to its acquisition of 13 independent animal hospitals with combined annual revenues of $26 million.
C.R. Bard provided more clarity around the launch strategy of the first FDA approved drug-coated balloon, the Lutonix 035 Drug Coated Balloon Catheter, during its third quarter earnings call today.
Startup Gamma Medica is aiming to improve the odds and lower the cost of effective imaging of dense breast tissue with its molecular breast imaging tool. Now, it's gained a cash infusion of $11.5 million to aid in its commercialization efforts.
Expect medical device companies to feel the squeeze from the advent of reference pricing, whereby patients must bear procedures' expenses that exceed a predetermined threshold.